{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:36:59Z","timestamp":1792442219967,"version":"4.5.0"},"reference-count":26,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,9,12]]},"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome represents a severe adverse drug reaction driven by eosinophilia. Treatment is focused on withdrawal of medication, supportive care and immunosuppression such as high-dose corticosteroid therapy. Here we report a 56-year-old male patient who initially presented with breathlessness and eosinophilia, subsequent development of respiratory failure and admission to ITU for non-invasive ventilation. The patient continued to deteriorate despite high-dose prednisolone and methylprednisolone. Other causes of hypereosinophilia were normal. He was diagnosed with DRESS syndrome secondary to pregabalin and was treated with subcutaneous mepolizumab. We observed the rapid resolution of eosinophilia and clinical improvement; the patient was discharged home within a month of administration. This represents the successful use of mepolizumab in the acute setting of pulmonary failure secondary to DRESS. A similar approach could be adopted in other acute conditions with refractory eosinophilic inflammation where standard steroid therapy has failed.<\/jats:p>","DOI":"10.1136\/bcr-2019-231355","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T08:05:18Z","timestamp":1570781118000},"page":"e231355","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Mepolizumab rescue therapy for acute pneumonitis secondary to DRESS"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct00097370","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03306043","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03306043","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00097370","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00097370","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03306043","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03306043","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0524-9449","authenticated-orcid":false,"given":"Onn Shaun","family":"Thein","sequence":"first","affiliation":[{"name":"Respiratory Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Sutton","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Thickett","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1508-8362","authenticated-orcid":false,"given":"Dhruv","family":"Parekh","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, UK"},{"name":"Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"key":"2025082701433989000_12.10.e231355.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)05418-X"},{"key":"2025082701433989000_12.10.e231355.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1085-5629(96)80038-1"},{"key":"2025082701433989000_12.10.e231355.3","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1996.03890350057010"},{"key":"2025082701433989000_12.10.e231355.4","first-page":"31","article-title":"Drug reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome","volume":"6","author":"Choudhary","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"key":"2025082701433989000_12.10.e231355.5","first-page":"286","article-title":"Eosinophils in asthma","volume":"68","author":"Busse","year":"1992","journal-title":"Ann Allergy"},{"key":"2025082701433989000_12.10.e231355.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70069-2"},{"key":"2025082701433989000_12.10.e231355.7","doi-asserted-by":"publisher","DOI":"10.1081\/JAS-63001"},{"key":"2025082701433989000_12.10.e231355.8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.2.542"},{"key":"2025082701433989000_12.10.e231355.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07704.x"},{"key":"2025082701433989000_12.10.e231355.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.01.017"},{"key":"2025082701433989000_12.10.e231355.11","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.145.1.67"},{"key":"2025082701433989000_12.10.e231355.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07807.x"},{"key":"2025082701433989000_12.10.e231355.13","unstructured":"UK N. Mepolizumab for treating severe refractory eosinophilic asthma. 2017 www.nice.org.uk\/guidance\/ta431 (cited 2017 14\/12\/2017)."},{"key":"2025082701433989000_12.10.e231355.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03496-6"},{"key":"2025082701433989000_12.10.e231355.15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200701-085OC"},{"key":"2025082701433989000_12.10.e231355.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"2025082701433989000_12.10.e231355.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2025082701433989000_12.10.e231355.18","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"key":"2025082701433989000_12.10.e231355.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070812"},{"key":"2025082701433989000_12.10.e231355.20","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaip.2017.10.020","article-title":"Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome successfully treated with mepolizumab","volume":"6","author":"Ange","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025082701433989000_12.10.e231355.21","first-page":"164","article-title":"A case report on gabapentin induced DRESS syndrome","volume":"3","author":"Valleti","year":"2017","journal-title":"World J Pharm Med Res"},{"key":"2025082701433989000_12.10.e231355.22","first-page":"1","article-title":"Successful Treatment of Antiepileptic Drug-Induced DRESS Syndrome with Pulse Methylprednisolone","volume":"2013","author":"Kocaoglu","year":"2013","journal-title":"Case Rep Pediatr"},{"key":"2025082701433989000_12.10.e231355.23","doi-asserted-by":"crossref","first-page":"709 e1","DOI":"10.1016\/j.jaad.2013.01.032","article-title":"DRESS syndrome: Part II. Management and therapeutics","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2025082701433989000_12.10.e231355.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2010.03967.x"},{"key":"2025082701433989000_12.10.e231355.25","unstructured":"GlaxoSmithKline. Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome. 2004. Clinical Trial NCT00097370]. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00097370?term=mepolizumab&draw=2&rank=19\u00a0[cited 2017 14\/12\/2017]."},{"key":"2025082701433989000_12.10.e231355.26","unstructured":"GlaxoSmithKline. A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622. 2017. Clinical Trial NCT03306043]. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03306043?term=mepolizumab&draw=1&rank=8\u00a0[cited 2017 14\/12\/2017]."}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-231355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:43:52Z","timestamp":1756284232000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-231355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10,10]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1136\/bcr-2019-231355"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-231355","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}